EDE’s medical division advances pharmaceuticals alongside real-time genomic sequencing, AMR detection and in vivo diagnostics, with solutions deployable across field, clinical and public health settings.
From 50-millisecond genome scans to the design of next-generation pharmaceuticals, EDE develops platforms that unite diagnostics and drug discovery to save lives and reduce suffering at scale. Our genomic technologies operate without the need for reagents, while our pharmaceutical pipeline uses AI-driven design and synthesis for faster, more precise therapeutics. Together, these capabilities are reshaping how the world approaches diagnostics, precision medicine and global health.
Used in labs, clinics, and infrastructure-scale rollouts.
Delivers results in under 50 milliseconds for critical-response use cases.
Our trials focus on infectious disease screening and genomic applications, with a clear pathway toward international regulatory approval.
Discovered, synthesized and tested.
Identifies, designs and synthesizes high‑value molecules for multiple disease areas, moving from concept to validated candidates in record time and with in‑house scalability.
Identifies resistance genes and guides treatment choices based on pathogen profiles, enabling better stewardship and reducing the spread of antimicrobial resistance worldwide.
Support for newborn and prenatal screening, oncology care, immune health, neurodegeneration, whole genome sequencing, and even food safety and veterinary health. All panels run on the same core platform, making advanced testing more accessible to patients and communities everywhere.
Built for public health scale: deployable in clinics, airports, or field hospitals. Used during COVID-19 and HIV programs across 200M+ tests globally.
EDE’s platforms unite advanced drug discovery with real-time diagnostics, enabling decentralised testing, personalised treatments and scalable responses that range from global health emergencies to precision medicine.
Designed to help pharmaceutical companies move from discovery to preclinical readiness quickly, with integrated design, synthesis and testing that eliminates common development bottlenecks.
Accurate sequencing and biomarker detection across blood, saliva, swabs and mixed samples in real time.
Capable of processing multiple samples simultaneously, supporting everything from clinical diagnostics to population-scale screening.
Candidates are discovered, synthesized and tested in-house, reducing timelines and enabling rapid iteration.
From drug discovery to diagnostics, EDE works with hospitals, researchers and scientific institutions to test and refine our platforms in real-world settings, advancing new therapeutics, improving disease control and enabling precision medicine.
